Chicago, July 01, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Nuclear Medicine Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology,Cardiology), Procedures - Global Forecast to 2026", is projected to reach USD 7.5 billion by 2026 from USD 4.8 billion in 2021, at a CAGR of 9.0% during the forecast period.

Browse in-depth TOC on "Nuclear Medicine Market/ Radiopharmaceuticals Market"
324- Tables
27- Figures
253- Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417

The Growth in the Radiopharmaceuticals Market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region.

Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.
.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=417

Based on application, the nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

Based on procedural volume assessment, the nuclear medicine market is segmented into diagnostic and therapeutic procedures. Diagnostic procedures account for the larger share, as diagnostic radioisotopes find wider demand and use as compared to therapeutic radioisotopes. Since the introduction of nuclear medicine, SPECT diagnosis has been preferred over other radiopharmaceutical procedures. Due to looming uncertainties in the production of reactor-based Mo-99, the radiopharmaceuticals market is witnessing a shift toward PET procedures.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=417

Geographical Growth Scenario:

Based, on region, the nuclear medicine market is segmented into— north America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the Radiopharmaceuticals Market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and initiatives by market players in this region.

Key Players in Nuclear Medicine Market / Radiopharmaceuticals Market:

• Cardinal Health (US),
• GE Healthcare (US),
• Curium (France),
• Lantheus Medical Imaging (US),
• Bayer AG (Germany),
• Bracco Imaging (Italy),
• Eczacýbaþý-Monrol Nuclear Products (Turkey),
• Nordion (Canada),
• Advanced Accelerator Applications (France), and
• NTP Radioisotopes (South Africa)
  

Browse Adjacent Markets: Pharmaceuticals Market Research Reports & Consulting

Browse Related Reports:

Radiation Detection, Monitoring, & Safety Market by Product (Detection & Monitoring (Personal Dosimeters), Composition (Gas-filled detectors, Scintillator, Solid-state detector), Application (Healthcare, Industrial Application) - Global Forecasts (2022 - 2026)
https://www.marketsandmarkets.com/Market-Reports/radiation-protection-market-987.html

North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024
https://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com